Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population

BMC Medical Genetics

Table 5 Association between different CYP19A1 SNP genotypes and the clinico-pathological features of breast cancer (BC)

Clinical features	CYP19A1
Clinical features	rs10046	rs7176005	rs700519	rs6493497	rs4646
Body mass index ^b n = 221	0.510	0.570	0.811	0.547	0.092
Age at first pregnancy ^b n = 195	0.122	0.200	0.825	0.200	0.956
Age at BC diagnosis ^b n = 221	0.007	0.681	0.836	0.789	0.921
Allergy ^a n = 221	0.936	0.935	0.401	0.967	0.856
Age at menarche ^b n = 221	0.989	0.421	0.044	0.405	0.383
Breastfeeding status ^a n = 221	0.401	0.095	0.367	0.127	0.721
Age at menopause ^b n = 108	0 .290	0.736	0 .002	0 .736	0.797
Family history ^a n = 221	0.571	0.121	0.927	0.138	0.123
Co-morbidity ^a n = 221	0.104	0.557	0.924	0.566	0.905
Smoking ^a n = 216	0.166	0.607	0.059	0.580	0.617
Pathological features
Progesterone receptor status ^a n = 198	0.157	0.754	0.867	0.719	0.755
Estrogen receptor status ^a n = 191	0.714	0.463	0.159	0.339	0.227
Human epidermal growth factor receptor 2 marker (HER2) ^a n = 139	0.945	0.445	0.493	0.485	0.468
Heteromolecular BC markers^a n = 138	0.510	0.788	0.915	0.797	0.754
Tumor differentiation ^a n = 197	0.273	0.851	0.918	0.860	0.906
Axillary lymph nodes ^a n = 221	0.844	0.793	0.584	0.687	0.297
Tumor stage ^a n = 208	0.491	0.118	0.922	0.080	0.236
Histology classification ^a n = 209	0.722	0.475	0.407	0.507	0.320
Tumor size ^b n = 208	0.726	0.547	0.879	0.472	0.448
Lymph node involvement ^a n = 221	0.953	0.681	0.617	0.691	0.022

^a Pearson’s chi-squared test was used to determine genotype-phenotype association
^b Analysis of variance (ANOVA) test was used to determine genotype-phenotype association
P-Value < 0.0045 considered as significant

ISSN: 1471-2350